Immunovant fiscal Q2 net loss narrows 23% to $97.25 million

• Immunovant’s net loss narrowed 23% year over year to $97.25 million in the fiscal second quarter ended September 30, 2026.
• Research and development expenses fell 26% year over year to $85.01 million, primarily due to winding down batoclimab trials and manufacturing-cost timing.
• Cash and cash equivalents totaled $722.3 million at September 30, providing runway to IMVT-1402’s potential Graves’ disease launch under current operating plans.
• IMVT-1402 met the primary endpoint in difficult-to-treat rheumatoid arthritis; FDA discussions on the registrational path are planned for later this year.
• Further IMVT-1402 development in Sjögren’s disease beyond the ongoing Phase 2 trial is unlikely, given the evolving landscape and recent field data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090700PRIMZONEFULLFEED9873093) on November 09, 2026, and is solely responsible for the information contained therein.